About DCAT Value Chain Insights

DCAT Value Chain Insights is a weekly electronic information resource of the Drug, Chemical & Associated Technologies Association (DCAT) delivered each Wednesday to DCAT member companies and found at www.DCATvci.org. DCAT Value Chain Insights consists of feature content (both staff-written and contributed articles from industry members).

Editorial Focus:

DCAT Value Chain Insights provides analysis of pharmaceutical/biopharmaceutical companies, contract service providers, and suppliers as well as regulatory/compendial developments that impact drug development and manufacturing, the supply chain, and related areas. DCAT Value Chain Insights covers manufacturing of drug substances (small molecules and biologics) and drug products (solid dosage, parenterals, and specialty dosage forms). It also covers formulation development/drug delivery, packaging, logistics/supply chain, sourcing, procurement, supply management, and other issues impacting sponsor company/supplier relationships. Articles offer executive insights, best practices, case-studies, and market analysis.

DCAT Value Chain Insights Audience:

Readers of DCAT Value Chain Insights are C-suite, senior and mid-level executives of the large and mid-sized pharmaceutical/biopharmaceutical companies who are involved in procurement, sourcing, supply management, and third-party/external manufacturing and the sales, marketing, business development, and manufacturing professionals of contract service providers and suppliers (i.e. chemicals, fine chemicals, contract API manufacturing [small molecules and biologics], contract formulation development and drug product manufacturing, packaging, and related services).

Editorial Contributions: DCAT Value Chain Insights welcomes article contributions from industry members (see next page for authors’ guidelines), op-ed/opinion pieces, suggestions for article ideas and research, and press releases reporting on company developments, including staff/personnel appointments. Below are some examples of feature articles:

API Supply Lines: Examining the Impact of the EU Falsified Medicines Directive and Global GMP Certifications

IMS Offers a Subdued Outlook for the Global Pharmaceutical Industry

FDA Begins Implementation Efforts for the Drug Supply Chain Security Act

Transforming Global Procurement a Key Goal for Teva in 2014

Executive Insights: DPx Holdings B.V. on the Road to Integration
Editorial Submissions: Feature Articles

Readers are familiar with overall industry trends and issues, and a given article should provide thought leadership by offering specific market insight or case-study analysis that would be of utility in readers’ work. Regard readers as part of an informed audience interested in advancing their understanding of industry issues and trends or in learning from solution-based case studies that facilitate their resolution of organizational, operational, and technical challenges. The articles may address leadership, organizational change, negotiation, strategy, operations, marketing, finance, managing people, or technology (i.e., manufacturing issues on an API or drug product level, formulation/drug delivery, or packaging). The article should be based on research and/or operational experience. *Editorial content that is promotional to a product or company will not be accepted.*

**Originality and Rights.** Article submissions are reviewed with the understanding that they have not been published previously in any formal (print or electronic), are not ghostwritten, and are not under consideration for publication elsewhere, including on the Internet or web-based outlets. The author and any co-authors are required to sign a license agreement before an article is accepted for publication to provide DCAT permission to publish the original article and its associated figures/tables.

**Illustrations, Images, Figures, and Table Rights.** The author and/or company of the author(s) must own the rights to all submitted images, tables, and figures. Graphics from other sources or third-party sources will not be accepted for publication. A credit is provided to the author(s) and/or the company providing the graphics.

**Article Specifications:**

- Article lengths should be between 1800 and 2500 words and submitted as a Word Document to Patricia Van Arnun, Editorial Director, DCAT, pvanarnum@dcat.org, Main line: 609.208.1888.

- It is recommended to have graphics (charts, tables, images) to provide visual interest and information to the reader. Generally two to four graphics are recommended, and a given article should not have more than six graphics. Graphics that do not advance the reader’s understanding should not be submitted. A callout to the graphic should be provided in the text of the article. Be sure to include descriptive captions and credit information for all figures and images.

- Graphics, such as images or charts, may be submitted as jps or eps files (jpg preferred) in high-resolution (300 dpi). Text tables may be submitted in Word or Excel.

- The illustrations, images, and figures must be original to the author(s) with appropriate source credit for the graphic. Graphics from third-party sources will not be accepted for publication.

- Articles accepted for publication will be edited/formatted for content and style. A proof of the article will be provided to the author(s) for review prior to publication. The publication date of the article will depend on the successful completion of the previously described editorial process. It is our intent to publish articles in a timely fashion.

- Contributing authors should provide name, title, and company affiliation.

Editorial Submissions: Op-Ed/Viewpoints

DCAT Value Chain Insights welcomes submissions for op-ed/viewpoint pieces to express an opinion on industry issues and trends. Such pieces may not be promotional to a product or company but be used to provide a thoughtful view of an industry trend or issue. Opinion pieces should be approximately 1000 to 1500 words and include the name and title of the submitting author. They may be submitted to Patricia Van Arnun, Editorial Director, DCAT, pvanarnum@dcat.org, Main line: 609.208.1888 for editorial consideration.

Such pieces must follow the same guidelines outlined above for feature articles. Submissions are reviewed with the understanding that they have not been published previously in any format (print or electronic), are not ghostwritten, and are not under consideration for publication elsewhere, including on the Internet. The author and any co-authors are required to sign a license agreement before an article is accepted for publication to provide DCAT permission to publish the original article and its associated figures/tables.
Editorial Contact:
Article submissions and editorial queries may be made to:

Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org.
Main Line: 609.208.1888

Patricia Van Arnum, Editorial Director, DCAT, has over 20 years of experience as a business and science editor and journalist, covering the pharmaceutical, biopharmaceutical, and fine-chemicals industries. Prior to joining DCAT, Ms. Van Arnum was Executive Editor of Pharmaceutical Technology from 2006 to 2014 and Executive Editor of ICIS Chemical Business and Chemical Market Reporter (CMR) from 1995–2005. She holds undergraduate degrees in chemistry, economics, and political science. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science.

The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, member-supported business development association for the global pharmaceutical manufacturing industry. DCAT is committed to providing programs, events, and services that help its members expand their network of customers, suppliers, and colleagues in the industry. For more information, visit DCAT’s website at www.dcat.org.